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has been shown to be essential for epi-
dermal progenitor cell function and 
is enriched in undifferentiated cells, 
where it suppresses differentiation and 
maintains proliferative properties (Sen 
et al., 2010). Interestingly, a proportion 
of genes repressed during differentiation 
become methylated de novo, and some 
genes lose methylation during this process. 
Thus, DNA methylation is a dynamic pro-
cess that occurs during epidermal differ-
entiation (Sen et al., 2010). In agreement 
with the observed aberrant keratinocyte 
differentiation and hyper proliferation, 
we were able to demonstrate upregulation 
of DNMT1 in psoriasis by approximately 
1.5-fold (Gudjonsson, unpublished obser-
vation). Interestingly, proinflammatory 
cytokines such as interleukin-6, which 
is increased in psoriasis, can induce the 
expression and activity of DNMT1 (Hodge 
et al., 2001). Much less is known about 
the regulation of demethylases in the epi-
dermis; this will be an interesting area for 
future research.
We have barely scratched the surface 
of the role of epigenetics in the skin. As 
technology progresses, and with it our 
ability to determine other types of epi-
genetic changes, we predict that a more 
complete view of the mechanisms oper-
ating in psoriatic plaques will emerge. 
Taken together, data from Roberson et 
al. (2012) indicate that DNA methyla-
tion in psoriasis is a dynamic process, 
influenced—and possibly even driven 
entirely—by the cytokine environment. 
These changes in the epigenome are 
likely to have a major role in orches-
trating the altered differentiation and 
proliferation observed in psoriatic 
lesions. Characterizing the mechanisms 
involved and the consequences of these 
changes are exciting avenues for future 
research.
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In this issue, Paek et al. describe two phenomena. First, they show that 
intermediate concentrations of a “transgenic” autoantigen may cause a 
lichen planus–like autoimmune disease. Second, and more importantly, they 
show that high doses of peptide antigen suppress the expression of the T-cell 
receptor and coreceptors, particularly CD8, and that this suppression improves 
this T-cell-mediated, destructive inflammatory skin disease that is similar to 
erosive lichen planus.
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T-cell tolerance resulting from recep-
tor downregulation was first described 
20 years ago (Schönrich et al., 1991). 
The long road between recognizing 
Clinical Implications
•  DNA methylation is one of several epigenetic mechanisms that can lead 
to stable and heritable changes in gene expression without changing 
the underlying DNA sequence.
•  Lesional skin in psoriasis is accompanied by changes in DNA 
methylation.
•  Changes in DNA methylation revert to baseline with treatment, 
indicating that in psoriasis it is dynamic.
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incoming threats be recognized as dan-
gerous by the adaptive immune system. 
In lymph nodes, innate information is 
translated and amplified through the 
activation of adaptive T cells and B cells. 
Highly efficient on a routine basis, this 
activation process may lead to errors at 
any one of three important checkpoints:
1.  Innate immune activation may 
be too sensitive to stimuli if 
either the activation or the 
silencing pathway includes 
regulation defects.
2.  Adaptive immunity may have 
silencing defects that result from 
either absent T-cell silencing or 
absent regulatory T cells (Tregs) 
(Sakaguchi, 2005; Shevach, 2011).
3.  Perpetuation of cytokine 
production may cause self-
destruction, as in the case of 
delayed-type hypersensitivity 
responses (DTHRs) that are 
associated with IFN-γ-producing 
Th1 or IL-17-producing Th17 cells.
Protection from autoimmune disease: 
three dimensions of functional 
T-cell tolerance
The thymus protects against autoim-
mune diseases by deleting potentially 
harmful, autoreactive T cells (Kisielow 
this fundamental biological phenom-
enon and its translation into an inflam-
matory skin disease (Gutermuth et al., 
2009; Paek et al., 2012, this issue) is 
of considerable scientific and clinical 
importance. Recent progress in clini-
cal dermatology illustrates the clini-
cal importance of the slow process of 
translating basic research into appropri-
ate model diseases and then into the 
development of appropriate therapies. 
One example is anti-CTLA4 therapy 
for human melanoma (Robert et al., 
2011), initially developed as immune 
therapy in mice with prostate cancer 
(Kwon et al., 1999). Other examples 
include the adoptive transfer of cancer-
specific, interferon (IFN)-γ-producing T 
helper type 1 (Th1) cells, developed as 
a treatment for model cancers in mice 
(e.g., Egeter et al., 2000) and now avail-
able as therapy for human melanoma 
(Hunder et al., 2008), and the finding 
that tumor necrosis factor (TNF) antag-
onists improve autoimmune diseases 
in mice (Santambrogio et al., 1993), 
which has been translated into a ther-
apy for psoriasis (Griffiths and Barker, 
2007). Cytokine-induced immune 
deviation developed to treat inflam-
matory diseases in mice (Racke et al., 
1994) has been translated into inter-
leukin (IL)-4 therapy (Ghoreschi et al., 
2003) and anti-IL-12/IL-23p40 therapy 
for psoriasis (Griffiths et al., 2010). 
Thus, translational research—the long 
road from basic descriptions through 
proof in appropriate models—may ulti-
mately improve human health.
Development of immune responses
Immune responses generally start by 
alerting the body’s immune system 
through innate signals; an innate alert 
is translated into an adaptive immune 
response that protects against viral, bac-
terial, or fungal infection (Matzinger, 
1994). Untreated T-cell-deficient 
infants with severe combined immune 
deficiency syndromes die early in life 
from severe infection (Felgentreff et 
al., 2011). More frequently, chronic 
infectious diseases result from defects 
in the development of appropriate 
T-cell-adaptive immunity. Disease may 
also develop in immune-competent 
individuals when innate or adaptive 
immune responses fail to neutralize 
pathogens efficiently; if pathogens per-
sist in significant numbers, the ongoing 
immune response itself may become 
harmful. Prominent examples include 
eczemas or cicatrizing folliculitis result-
ing from persistent trichophyton infec-
tion, liver fibrosis resulting from the 
persistent interaction between T cells 
and viruses in chronic hepatitis C, and 
HIV infection. In these circumstances, 
disease results from immune-mediated 
destruction of macrophages and T cells.
A third group of inflammatory diseas-
es results from inappropriate activation 
of either innate or adaptive immune 
responses or both. Autoinflammatory 
diseases are examples of inappropriate 
activation of innate immunity (Kastner 
et al., 2010); inappropriate activation 
of adaptive immunity leads to diseas-
es such as pemphigus (Getsios et al., 
2010), lichen planus, and vitiligo (Lang 
et al., 2001). Both innate and adap-
tive immune activation are critically 
involved in psoriasis. Consequently, 
therapeutically targeting either adaptive 
T cells or innate immunity ameliorates 
psoriasis in most patients (Ghoreschi et 
al., 2003, 2011).
Diseases resulting from aberrant 
immune activation
Natural barriers and early innate 
responses routinely cope with most 
potential threats. Only rarely must 
Figure 1. Fluorescent in situ hybridization analysis showing single donor-derived male cells in the oral 
mucosa 6 weeks after transplantation of male bone marrow cells into a C57/BL6 female mouse. White 
arrow points to donor-derived male cell. Red, Y chromosome; green, X chromosome.
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et al., 1988). Similarly, strong stimula-
tion in the periphery may cause T-cell 
deletion (Paek et al., 2012; Röcken et 
al., 1992). Other peripheral mecha-
nisms leading to T-cell tolerance are 
functional T-cell silencing, the induc-
tion of Tregs, and functional immune 
deviation (a treatment already in prac-
tice through the use of anti-IL-12/IL-23 
monoclonal antibodies).
Functional T-cell silencing. Functional 
T-cell silencing may result from 
T-cell “over”-activation or from 
activation in the absence of appro-
priate costimulation. Thus, in vivo 
over activation, sometimes also called 
high-zone tolerance, may lead to 
the failure of T cells to respond, nei-
ther proliferating nor producing cyto-
kines in response to antigenic stimuli 
(Moskophidis et al., 1993; Röcken et 
al., 1992). Frequently, functional T-cell 
tolerance is determined by the inabil-
ity of T cells to produce IL-2 or IFN-γ or 
to proliferate in response to appropri-
ate antigenic stimulation. Anergy and 
exhaustion can be explained in part 
by defects in the T-cell receptor (TCR) 
signaling cascade (Saibil et al., 2007). 
Alternatively (or, more likely, in addi-
tion), T-cell anergy results from suppres-
sion in the expression of the TCR and 
coreceptors, such as CD4 and CD8, 
which are required for T-cell activation 
(Schönrich et al., 1991). In this issue, 
Paek et al. (2012) demonstrate that con-
tinuous application of high concentra-
tions of specific peptides results in TCR 
suppression and T-cell anergy. More 
importantly, they also demonstrate 
that intermediate concentrations of the 
peptides may cause severe, destruc-
tive inflammatory skin inflammation. 
Increasing the antigen concentrations 
via continuous peptide therapy func-
tionally silences T cells by suppress-
ing TCR and CD8 expression, leading 
to the generation of T cells that are 
no longer capable of damaging skin. 
High-dose peptide therapy may thus 
be a valuable therapeutic approach 
for T-cell-mediated diseases. Yet, this 
sort of therapy will have several critical 
prerequisites, one of which is the iden-
tification of the key peptide that is rec-
ognized by the T cells that may cause 
human autoimmune disease.
Moreover, the disease should be 
strictly T-cell mediated, such as in lichen 
planus, alopecia areata, and vitiligo. 
Successful treatment of lichen planus 
would still require the identification of 
the relevant peptides. Vitiligo appears 
to be a candidate because data suggest 
that it is initiated and caused by melan 
A–specific CD8 T cells (Lang et al., 
2001). Yet it remains uncertain whether 
suppression of melan A–specific Th1 or 
Tc1 cells increases the risk of melanoma 
(Müller-Hermelink et al., 2008; Ziegler 
et al., 2009). In humans, B-cell-mediated 
autoimmune diseases, particularly pem-
phigus vulgaris and pemphigus folia-
ceus, share many similarities. This is 
especially true for the endemic Brazilian 
disease pemphigus foliaceus. T- and 
B-cell epitopes depend on autoreactive 
T cells capable of stimulating B cells for 
the production of disease-causing auto-
antibodies (Getsios et al., 2010).
Unfortunately, T-cell anergy estab-
lishes labile equilibrium because it may 
be overcome by infections that cause 
general T-cell expansion (Röcken et al., 
1994). Another risk is inappropriate 
activation of potentially harmful T cells 
(Bielekova et al., 2000).
Tregs. Besides achieving a state of 
anergy or unresponsiveness, activated T 
cells may achieve a state in which they 
actively silence neighboring T cells. 
Such Tregs express the IL-2 receptor 
CD25, reflecting their activated status. 
The most important characteristic of 
Tregs is their expression of the transcrip-
tion factor FoxP3. Tregs suppress coacti-
vated T cells through contact-dependent 
mechanisms and through the produc-
tion of IL-10 or transforming growth 
factor-β (TGF-β). The functional impor-
tance of Tregs was demonstrated either 
by deleting FoxP3-expressing T cells 
with anti-CD25 antibodies or by genet-
ic Foxp3 knockout (Sakaguchi, 2005; 
Shevach, 2011). Animals devoid of Treg 
cells develop severe autoimmune dis-
eases, with inflammatory destruction 
of multiple organs and severe wasting 
(Lahl et al., 2007). Because Tregs are 
difficult to generate in vivo through anti-
gen-specific stimulation or to expand in 
vitro in sufficient amounts for clinical 
use, their therapeutic potential remains 
uncertain.
Immune deviation. From the therapeu-
tic point of view, immune deviation (in 
which IFN-γ-dominated Th1 or IL-17-
mediated Th1 responses are deviated 
into IL-4-dominated Th2 responses that 
fail to cause efficient DTHRs) is the 
most advanced mode of functional 
T-cell silencing. This was originally 
shown in mice developing immunity 
to Leishmania major, in which immune 
deviation caused susceptibility to the 
parasite (Sadick et al., 1990). It was 
subsequently demonstrated that in vivo 
activation of CD4+ T cells in the pres-
ence of IL-4 deviates the developing 
Th1/Th17 responses into Th2 responses 
and thus abrogates T-cell-mediated con-
trol of parasite infections and endog-
enous cancer (Biedermann et al., 2001; 
Müller-Hermelink et al., 2008; Röcken 
et al., 1994). Deviation of Th1/Th17 into 
Th2 responses requires IL-4 and allows 
the prevention, and even treatment, 
of harmful DTHRs. This was shown 
for experimental encephalitis in mice 
(Racke et al., 1994; Ghoreschi et al., 
2011), psoriasis in humans (Ghoreschi 
et al., 2003, 2011; Griffiths et al., 2010), 
and probably also multiple sclerosis 
(Kappos et al., 2008).
Although peptide-mediated suppres-
sion of T-cell function, as shown by Paek 
et al. (2012) and in a model of diabetes, 
may help in some individuals whose 
response is strongly restricted to either 
CD4 or CD8 T cells, such therapies bear 
the risk of inappropriate immune acti-
vation, seem to have a short window of 
opportunity as diabetes develops, and 
require an individualized peptide vac-
cine for each patient (Paek et al., 2012; 
Bielekova et al., 2000). Thus, therapeu-
tic immune deviation that primarily 
targets T cells (Biedermann et al., 2001; 
Ghoreschi et al., 2003) or mononuclear 
and dendritic cells (Ghoreschi et al., 
2011; Hoetzenecker et al., 2012) may 
represent a safer therapy that also can 
be standardized.
|
Peptide-induced 
tolerance may be most 
useful as preparation 
before organ 
transplantation. 
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New clinical fields for 
functional T-cell tolerance
The most obvious example of function-
al T-cell tolerance in medical practice 
occurs after bone marrow or—less fre-
quently—solid-organ transplantation. 
In this newly developing field, tissues 
will be replaced by the transplanta-
tion of either somatic cells generated in 
vitro from pluripotential precursors or 
cells expressing a missing neo-antigen. 
Although somatic cells, generated in 
vitro from adipocytes, express neo-anti-
gens at the time of transplantation, pre-
liminary data from veterinary medicine 
suggest that they can serve appropriate-
ly in replacement therapy (Richardson 
et al., 2007). Hosts may even toler-
ate real neo-antigens. Thus, in mice, 
transplantation of various precursor 
cells allows long-lasting engraftment, 
even of cells that express immunogenic 
peptides, such as those derived from 
the HY gene (Figure 1) or enhanced 
green fluorescent protein. The data 
described by Paek et al. (2012) suggest 
that induction of peptide-specific toler-
ance should allow tolerance induction 
toward highly immunogenic protein 
antigens. Because, in this case, the 
neo-antigen is well known, it is suitable 
for specific desensitization. Therefore, 
peptide-induced tolerance as presented 
in this report may be most relevant 
for the immunological preparation of 
recipients for replacement therapy in 
patients with defined genetic defects.
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